- Abstract
E-Manuscript Article Summaries
- Current Oncology Editorial Office
CML Biology for the Clinician in 2011: Six Impossible Things to Believe Before Breakfast on the Way to Cure [...]
August 2011 - 13 articles
CML Biology for the Clinician in 2011: Six Impossible Things to Believe Before Breakfast on the Way to Cure [...]
Since the start of the 1990s, molecular pathology has been playing an increasingly important role in cancer diagnosis and treatment.[...]
Patients with head-and-neck cancer constitute one of the diagnostic groups that most commonly experi-ence deterioration of nutrition status.[...]
There are at least 5 types of kisses, including ges-tural, cultural, osculum, basium, saviolum, and oro-genital.[...]
Background: In 2007, the Government of Newfoundland and Labrador established the Commission of Inquiry on Hormone Receptor Testing to examine problems with estrogen and progesterone hormone receptor tests conducted in the province between 1997 and 20...
Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes and lacks common therapeutic targets, including HER 2 and the estrogen and progesterone receptors. The clinicopathological heterogeneity of the disease and limited t...
Using a retrospective chart review, we investigated the differences in survival and prognostic factors between patients with triple-negative breast cancer (tnbc) and those with non-tnbc. The review included 1018 breast cancer patients who were diagno...
For advanced and metastatic prostate cancer, androgen deprivation therapy (adt) is the mainstay of treatment. Awareness of the potential bone-health complications consequent to adt use is increasing. Many studies have shown that prolonged adt leads t...
Morphologic features of tumour cells have long been validated for the clinical classification of breast cancers and are regularly used as a “gold standard” to ascertain prognostic outcome in patients. Identification of molecular markers such as expre...
Monoclonal antibodies against the epidermal growth factor receptor (anti-egfr) when used in the treatment of metastatic colorectal cancer are associated with improved survival. Patients whose tumours harbor a KRAS mutation in codon 12 or 13 have been...
of 2